Open access
Open access
Powered by Google Translator Translator

RCT: Effect of high-dose subcutaneous Semaglutide vs. placebo in adults with overweight or obesity

25 Feb, 2021 | 08:52h | UTC

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial – JAMA

Commentary: Semaglutide paired with intensive behavioral therapy showed triple weight loss vs placebo – University of Pennsylvania School of Medicine

Related study: Once-weekly, high-dose semaglutide is effective for improving overweight or obesity among non-diabetic adults – New England Journal of Medicine (study and commentary)


Commentary on Twitter


Stay Updated in Your Specialty

Telegram Channels

WhatsApp alerts 10-day free trial

No spam, just news.